PDGFRA and glioblastoma: Since clinical trials targeting PDGFRA with kinase inhibitors have been largely unsuccessful, therapeutic strategies involving antisense oligonucleotides or decoy RNAs to disrupt the LINC02283–PDGFRA interaction could be an approach to combat GBM malignancy [129].